Huadong Medicine's Unit Gets Joint Rights to Quanxin Bio's Anti-Inflammatory Drug

MT Newswires Live07-22

Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, obtained exclusive joint development and marking rights for the drug QX005N from Jiangsu Quanxin Biopharmaceutical, according to the company's filing on the Shenzhen Stock Exchange.

Sino-US Huadong Pharmaceutical will be able to market the drug in authorized areas and Quanxin Bio will be responsible for the drug's production, supply, and quality control. Both parties will jointly carry out clinical research on the drug.

Both parties bear 50% each of the registration fees, the Chinese pharmaceutical company said in its filing.

The drug treats atopic dermatitis, nodular prurigo, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, asthma, and chronic obstructive pulmonary disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453782644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-22 11:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453782644","market":"fut","top_or_hot":-1,"title":"Huadong Medicine's Unit Gets Joint Rights to Quanxin Bio's Anti-Inflammatory Drug","media":"MT Newswires Live","content":"<html><body><p> Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, obtained exclusive joint development and marking rights for the drug QX005N from Jiangsu Quanxin Biopharmaceutical, according to the company's filing on the Shenzhen Stock Exchange.</p><p>Sino-US Huadong Pharmaceutical will be able to market the drug in authorized areas and Quanxin Bio will be responsible for the drug's production, supply, and quality control. Both parties will jointly carry out clinical research on the drug.</p><p>Both parties bear 50% each of the registration fees, the Chinese pharmaceutical company said in its filing.</p><p>The drug treats atopic dermatitis, nodular prurigo, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, asthma, and chronic obstructive pulmonary disease.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huadong Medicine's Unit Gets Joint Rights to Quanxin Bio's Anti-Inflammatory Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuadong Medicine's Unit Gets Joint Rights to Quanxin Bio's Anti-Inflammatory Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-22 11:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, obtained exclusive joint development and marking rights for the drug QX005N from Jiangsu Quanxin Biopharmaceutical, ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4185","symbol_name":"保健护理机构","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2453782644","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453782644","pubTimestamp":1721619877,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Huadong Medicine's  unit, Hangzhou Sino-US Huadong Pharmaceutical, obtained exclusive joint development and marking rights for the drug QX005N from Jiangsu Quanxin Biopharmaceutical, according to the company's filing on the Shenzhen Stock Exchange.Sino-US Huadong Pharmaceutical will be able to market the drug in authorized areas and Quanxin Bio will be responsible for the drug's production, supply, and quality control. Both parties will jointly carry out clinical research on the drug.Both parties bear 50% each of the registration fees, the Chinese pharmaceutical company said in its filing.The drug treats atopic dermatitis, nodular prurigo, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, asthma, and chronic obstructive pulmonary disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4185":"保健护理机构","000963":"华东医药","BK0175":"白马股","BK0188":"融资融券","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0132":"高送转概念","BK0187":"一线龙头","BK0183":"MSCI概念","BK0209":"零售","JYNT":"The Joint Corp.","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0196":"行业龙头"},"translate_title":"华东医药旗下单位获得全信生物抗炎药联合权益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JYNT":1,"000963":0.9},"content_text":"Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, obtained exclusive joint development and marking rights for the drug QX005N from Jiangsu Quanxin Biopharmaceutical, according to the company's filing on the Shenzhen Stock Exchange.Sino-US Huadong Pharmaceutical will be able to market the drug in authorized areas and Quanxin Bio will be responsible for the drug's production, supply, and quality control. Both parties will jointly carry out clinical research on the drug.Both parties bear 50% each of the registration fees, the Chinese pharmaceutical company said in its filing.The drug treats atopic dermatitis, nodular prurigo, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, asthma, and chronic obstructive pulmonary disease.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453782644"}